Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH

Last updated: February 25, 2025
Sponsor: Dr Sudarshan Rajagopal
Overall Status: Active - Recruiting

Phase

3

Condition

N/A

Treatment

Riociguat

Macitentan Tablets

balloon pulmonary angioplasty

Clinical Study ID

NCT05140525
Pro00105903
  • Ages > 18
  • All Genders

Study Summary

The main goal of this study is to determine the effects of combination medical therapy (Riociguat and Macitentan) and balloon pulmonary angioplasty (BPA) on hemodynamics and right ventricular (RV) function (including advanced assessments of RV-pulmonary artery (PA) coupling from invasive hemodynamics) in participants with inoperable or post-PTE residual CTEPH.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:

  1. Age ≥ 18 years' old

  2. Diagnosis of CTEPH

  3. Not a candidate for PTE

  4. Candidate for BPA based on suitable anatomy and disease burden

  5. Treatment-naïve (no CTEPH or pulmonary arterial hypertension (PAH)-specific medicaltherapies) with plans for initiation of CTEPH/PAH-specific medical therapy andtreatment with BPA.

  6. Willing and able to give informed consent and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed).

Exclusion

Exclusion Criteria:

  • Subjects presenting with any of the following will not be included in the trials:
  1. Moderate to severe heart disease (LVEF < 45% or severe LV Hypertrophy)

  2. Sarcoidosis

  3. Active cancer

  4. Sickle cell anemia

  5. Liver disease (Childs-Pugh class C)

  6. Prisoners

  7. Pregnant, planning pregnancy or lactating

  8. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia,inability to lie supine)

  9. Contraindication to riociguat or macitentan

  10. Medical or psychological conditions which, in the opinion of the investigator,might create undue risk to the subject or interfere with the subject's abilityto comply with the protocol requirements

Study Design

Total Participants: 15
Treatment Group(s): 3
Primary Treatment: Riociguat
Phase: 3
Study Start date:
January 27, 2025
Estimated Completion Date:
December 31, 2026

Study Description

Recent presented but unpublished results from trials of BPA vs riociguat for inoperable CTEPH (NCT02634203) have demonstrated that BPA provides a more significant hemodynamic benefit than medical therapy. The investigators hypothesize that participants who are treated with upfront combination medical therapy followed by BPA will have significant improvements in their hemodynamics and RV-PA coupling that can be monitored over time.

Connect with a study center

  • Duke University Medical Center

    Durham, North Carolina 27710
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.